Compared to LPV/r with nucleoside/nucleotide reverse transcriptase inhibitors (Control) what was the result of Lopinavir/ritonavir (LPV/r) and raltegravir (RAL) on VL <200 copies/mL at 96 weeks?
At 96 weeks, both RAL and Control maintained efficacy greater than 75% and continued to demonstrate similar safety profiles.